Tobias Sejbaek1, Mads Nybo2, Thor Petersen3, Zsolt Illes4. 1. Department of Neurology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Electronic address: Tobias.Sejbaek.Mathiesen@rsyd.dk. 2. Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark. 3. Department of Neurology, Aarhus University Hospital, Aarhus, Denmark. 4. Department of Neurology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Abstract
BACKGROUND: Dimethyl fumarate (DMF) has been registered for the treatment of relapsing-remitting multiple sclerosis (RRMS). Differences in tolerability between multiple sclerosis clinics in patients treated with DMF has not been examined. AIM: We examined real-world tolerability to DMF, and also compared adherence data between two MS clinics. METHODS: Adverse events (AE), discontinuation rates, and causes of discontinuation were investigated. RESULTS: 253 patients participated in this retrospective study. In the total cohort, 27.7% of the patients discontinued DMF. Higher rate of discontinuation was associated with higher number of previous disease modifying treatments (p < 0.001). Reasons for discontinuation were primarily flushing (15%) and gastrointestinal AEs (51%). Grade III lymphopenia was detected only in 6 cases (2.4%). We observed differences between the two clinics: discontinuation because of AEs was different (Odds ratio 6.13, 95% CI: 3.0-12.7, p < 0.001), the mean treatment duration also differed (305.3 ± 186.3 vs 140.5 ± 114.4 days, p < 0.001), and dissimilarities in adherence were mainly related to flushing, gastrointestinal AEs, and consideration of lymphopenia (p < 0.0001). Better adherence was associated with prospectively planned management of gastrointestinal AEs and flushing. CONCLUSION: Adherence in real-life was similar to pivotal trials. Differences in discontinuation rates at two MS clinics underline importance of AE management.
BACKGROUND:Dimethyl fumarate (DMF) has been registered for the treatment of relapsing-remitting multiple sclerosis (RRMS). Differences in tolerability between multiple sclerosis clinics in patients treated with DMF has not been examined. AIM: We examined real-world tolerability to DMF, and also compared adherence data between two MS clinics. METHODS: Adverse events (AE), discontinuation rates, and causes of discontinuation were investigated. RESULTS: 253 patients participated in this retrospective study. In the total cohort, 27.7% of the patients discontinued DMF. Higher rate of discontinuation was associated with higher number of previous disease modifying treatments (p < 0.001). Reasons for discontinuation were primarily flushing (15%) and gastrointestinal AEs (51%). Grade III lymphopenia was detected only in 6 cases (2.4%). We observed differences between the two clinics: discontinuation because of AEs was different (Odds ratio 6.13, 95% CI: 3.0-12.7, p < 0.001), the mean treatment duration also differed (305.3 ± 186.3 vs 140.5 ± 114.4 days, p < 0.001), and dissimilarities in adherence were mainly related to flushing, gastrointestinal AEs, and consideration of lymphopenia (p < 0.0001). Better adherence was associated with prospectively planned management of gastrointestinal AEs and flushing. CONCLUSION: Adherence in real-life was similar to pivotal trials. Differences in discontinuation rates at two MS clinics underline importance of AE management.
Authors: E D'Amico; A Zanghì; M Sciandra; G Borriello; G Callari; A Gallo; G Salemi; S Cottone; M Buccafusca; P Valentino; R B Bossio; L M E Grimaldi; C Pozzilli; G Tedeschi; M Zappia; F Patti Journal: J Neurol Date: 2018-12-04 Impact factor: 4.849
Authors: Paulus S Rommer; Ron Milo; May H Han; Sammita Satyanarayan; Johann Sellner; Larissa Hauer; Zsolt Illes; Clemens Warnke; Sarah Laurent; Martin S Weber; Yinan Zhang; Olaf Stuve Journal: Front Immunol Date: 2019-07-11 Impact factor: 7.561
Authors: Ana Rodríguez-Regal; Laura Ramos-Rúa; Luis Anibarro-García; Ana María Lopez Real; María Del Campo Amigo-Jorrín Journal: Patient Prefer Adherence Date: 2021-01-29 Impact factor: 2.711
Authors: Trudy L Campbell; Béatrice Jenny Lefaux; Lori Lee Mayer; Marie Namey; Gisela Riemer; Miguel A Robles-Sanchez; Sarah White; Michael Edwards; Charles Minor Journal: J Neurosci Nurs Date: 2020-04 Impact factor: 1.627